Detailed Narrative
CDMO Segment Drives Outperformance
The CDMO business was the standout performer in Q2 FY25, growing 24% YoY. This growth is increasingly driven by innovation-related work, specifically on-patent commercial manufacturing, which now accounts for approximately 70% of the CDMO mix. Management noted that this is the 6th consecutive quarter of both revenue growth and EBITDA margin expansion for this segment, signaling a successful turnaround from the post-pandemic slump.
Strategic Pivot to Differentiated Injectables
Piramal is doubling down on high-value, differentiated services with an $80 million investment in its Lexington, Kentucky facility. This expansion will double the site's capacity for sterile fill-finish, targeting the current global supply-demand gap in injectables. The facility is expected to be commercialized by the end of FY27 and will play a critical role in Piramal's integrated Antibody-Drug Conjugate (ADC) programs.
India Consumer Healthcare's Digital Acceleration
The ICH business is successfully transitioning to an omnichannel model, with online sales growing over 30% YoY and now contributing nearly 20% of segment revenue. Power brands like Tetmosol and Little's grew 18% during the quarter. Management is using e-commerce as a pilot ground, launching nearly 200 SKUs online over the last four years before rolling them out to general trade.
Complex Hospital Generics Facing Mixed Dynamics
While the inhalation anesthesia portfolio continues to see steady volume growth in the US and emerging markets, the injectable pain management segment has been slowed by supply constraints. Additionally, a pricing event with a major US GPO that began in Q3 of the previous fiscal year has impacted year-on-year comparisons, though management expects this effect to normalize after the current quarter.
Financial Discipline and FY30 Roadmap
Despite a high effective tax rate of over 50%, Piramal is maintaining its guidance for early teens growth in FY25. The company is focused on operating leverage and cost optimization to drive EBITDA growth faster than revenue growth. The long-term goal remains to reach $2 billion in revenue by FY30 while significantly deleveraging the balance sheet to a 1x net debt-to-EBITDA ratio.